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Abstract
Objectives: This meta-analysis aimed to determine the effectiveness of prehospital continuous positive
airway pressure (CPAP) or bilevel inspiratory positive airway pressure (BiPAP) in acute respiratory
failure.
Methods: Fourteen electronic databases and research registers were searched from inception to August
2013. Randomized or quasi-randomized controlled trials that reported mortality or intubation rate for
prehospital CPAP or BiPAP were selected and compared to a relevant comparator in patients with acute
respiratory failure. An aggregate data network meta-analysis was used to jointly estimate intervention
effects relative to standard care. A network meta-analysis using a mixture of individual patient-level data
and aggregate data was carried out to assess potential treatment effect modiﬁers.
Results: Eight randomized and two quasi-randomized controlled trials (six CPAP, four BiPAP,
sample sizes 23 to 207) were identiﬁed. The aggregate data network meta-analysis suggested that CPAP
was the most effective treatment in terms of mortality (probability = 0.989) and intubation
rate (probability = 0.639) and reduced both mortality (odds ratio [OR] = 0.41; 95% credible interval
[CrI] = 0.20 to 0.77) and intubation rate (OR = 0.32; 95% CrI = 0.17 to 0.62), compared to standard care.
The effect of BiPAP on mortality (OR = 1.94; 95% CrI = 0.65 to 6.14) and intubation rate (OR = 0.40; 95%
CrI = 0.14 to 1.16) was uncertain. The network meta-analysis using individual patient-level data and
aggregate data suggested that sex was a modiﬁer of the effect of treatment on mortality.
Conclusions: Prehospital CPAP can reduce mortality and intubation rates compared to standard care,
while the effectiveness of prehospital BiPAP is uncertain.
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Acute respiratory failure is a common but life-threatening medical emergency, especially inelderly patients with respiratory and cardiac
diseases.1–3 It is caused by a number of common cardiac
or respiratory conditions, including heart failure,
pneumonia, and exacerbation of chronic obstructive
pulmonary disease. The deﬁnitive treatment of acute
respiratory failure depends on the underlying cause, but
patients often require prehospital treatment. At this
point it is difﬁcult to accurately determine the underly-
ing cause, so prehospital treatment of acute respiratory
failure often follows a common pathway, rather than
being speciﬁc to the underlying cause.
Noninvasive ventilation (NIV) can be used to treat
acute respiratory failure.4–6 It involves providing respi-
ratory support through a tight-ﬁtting mask that is
usually applied around the patient’s mouth and nose
and may take the form of continuous positive airway
pressure (CPAP) or bilevel inspiratory positive airway
pressure (BiPAP), including noninvasive pressure sup-
port ventilation. It is normally used in the hospital, but
it may be more effective if treatment is commenced
prior to arrival.7 Prehospital NIV is considered in some
guidelines,8,9 but widespread use is limited by the need
for additional training and equipment and may be
informed by robust evidence of clinical effectiveness
and cost-effectiveness.
Prehospital NIV has been evaluated in a number of
studies, which have been summarized in systematic
reviews10–12 and meta-analysis.13,14 These suggest that
prehospital NIV, and speciﬁcally prehospital CPAP, can
improve outcomes. Existing systematic reviews have
been limited by failure to undertake meta-analyses,10–12
inclusion of nonrandomized studies in the meta-analy-
ses,13 failure to include studies only published in abstract
form,14 analysis of CPAP and BiPAP together,14 lack of a
network meta-analysis to compare CPAP and BiPAP,13,14
and lack of individual patient data meta-regression
to explore potential causes of heterogeneity.13,14 We
aimed to address these limitations by undertaking a
systematic review, aggregate data network meta–analy-
sis, and individual patient data meta-analysis of
randomized and quasi-randomized controlled trials to
determine the effect of prehospital CPAP and BiPAP on
mortality (primary outcome) and endotracheal intubation
(secondary outcome), in patients with acute respiratory
failure.
METHODS
We undertook a systematic review in accordance with
the general principles recommended in the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement15 and the checklist for
the review of evidence synthesis for decision-making.16
The review was registered on the PROSPERO interna-
tional prospective register of systematic reviews
(CRD42012002933), and the protocol is available at
http://www.nets.nihr.ac.uk/projects/hta/113609.
Eligibility Criteria
We included randomized or quasi-randomized con-
trolled trials that compared prehospital CPAP or BiPAP
to a relevant comparator treatment in patients with
acute respiratory failure.
Information Sources
The following electronic databases and research regis-
ters were searched from inception to August 2013:
MEDLINE In-Process & Other Non-Indexed Citations
and MEDLINE, EMBASE, Cumulative Index to Nursing
and Allied Health Literature, Cochrane Database of
Systematic Reviews, Cochrane Central Register of Con-
trolled Trials, Health Technology Assessment Database,
Database of Abstracts of Review of Effects, BIOSIS
Previews, Science Citation Index Expanded, Conference
Proceedings Index-Science, UK Clinical Research Net-
work Portfolio Database, National Research Register
Archive, Current Controlled Trials, and ClinicalTri-
als.gov. Searches were supplemented by hand-search-
ing the reference lists and performing a citation search
of relevant articles, contacting key experts in the ﬁeld,
and undertaking systematic keyword searches of the
internet using the Google search engine. No language
or date restrictions were used on any database. Details
of the search strategies are provided in Data Supple-
ment S1 (available as supporting information in the
online version of this paper).
Study Selection
All titles were examined for inclusion by one reviewer
(EP) and any citations that clearly did not meet the
inclusion criteria (e.g., nonhuman, unrelated to acute
respiratory failure) were excluded. All abstracts and full
text articles were then examined independently by two
reviewers (EP, AP). Any disagreements in the selection
process were resolved through discussion.
Data Collection Process
Data abstraction was performed by one reviewer (EP)
onto a standardized data extraction form and indepen-
dently checked for accuracy by a second (AP). Discrep-
ancies were resolved by discussion between the two
reviewers, and if agreement could not be reached, a
third reviewer (SG) was consulted. Where multiple pub-
lications of the same study were identiﬁed, data were
extracted and reported as a single study.
Data Items
The following information was extracted for all studies
when reported: study characteristics (author, year of
publication, country, study design, setting, duration of
follow-up, funding), participant details (age, sex, diag-
nosis, comorbidities, baseline physiology), intervention
(system used, pressure(s) used, duration of treatment,
practitioners providing intervention), comparator (any
use of NIV, supplemental oxygen), details including
information on any speciﬁed cotreatments, and out-
comes (including deﬁnitions). The authors of all
included studies were contacted to clarify details, obtain
missing data, and request individual patient data for
meta-analysis.
Assessment of Risk of Bias in Individual Studies
The methodologic quality of each included study was
assessed by one reviewer (EP) and independently
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checked by another (AP) to ensure consistency. In cases
of disagreement a third reviewer (SG) was consulted.
The study quality characteristics were assessed accord-
ing to adapted criteria based on those proposed by
Verhagen et al.17 for randomized clinical trials.
Summary Measures
Results of the network meta-analysis are presented as
odds ratios (OR) and 95% credible intervals (CrIs) rela-
tive to the baseline intervention (i.e., standard care). The
95% CrIs represent the 95% probability that the true
underlying effect lies in the interval speciﬁed. The
between-study standard deviations (SDs) together with
their 95% CrIs are also presented.
Planned Methods of Analysis
A random-effects network meta-analysis of aggregate
data of the number of events (i.e., mortality and intuba-
tion) was conducted using Markov chain Monte Carlo
simulation to jointly estimate the intervention effects rel-
ative to standard care.18 Separate one-stage random
effects network meta-regressions using a mixture of
individual patient data and aggregate data (where indi-
vidual patient data were not available) were carried out
to assess whether study characteristics (i.e., age, sex,
provider, primary diagnosis, and severity of acute respi-
ratory failure) were treatment effect modiﬁers. Any
missing covariates in the individual patient data were
assumed missing completely at random and were
imputed using multiple imputation.
Sensitivity analyses were planned to explore the
potential sources of heterogeneity, in particular whether
CPAP or BiPAP was used and whether prehospital pro-
viders were paramedics or physicians. In the event,
these issues were explored in the network meta-analysis
and meta-regression. A post hoc sensitivity analysis
was undertaken excluding quasi-randomized trials from
the network meta-analysis of aggregate data.
We performed separate analyses of the aggregate
data using different prior distribution for the between-
study SDs (i.e., a vague Uniform(0,2)) prior distribution
and two weakly informative prior distributions (i.e.,
Half-Normal(0,0.322) and Half-Normal(0,0.402)). A Uni-
form(0,2) prior distribution for a between-study SD
implies that we believe a priori that extreme heteroge-
neity is plausible and as likely as mild heterogeneity.
The conclusions and point estimates were consistent
across the three analyses and, as we would expect, the
CrIs for the ORs were slightly narrower when weakly
informative prior distributions were used. A vague
prior distribution for a between-study SD is not nonin-
formative when there are relatively few studies, as we
have in this case, so results of the aggregate and
individual patient data meta-analyses are based on
using Half-Normal(0,0.402) prior distributions for the
between-study SDs.
Convergence of the Markov chains to their stationary
distributions was assessed using the Gelman-Rubin sta-
tistic.19 The Markov chains in each aggregate data net-
work meta-analysis converged quickly and we used a
burn-in of 10,000 iterations. The Markov chains in the
mixed individual patient data and aggregate data net-
work meta-analyses took longer to converge and we
used a burn-in of 50,000 iterations. Parameters were
estimated based on 10,000 iterations of the Markov
chains after thinning them by retaining every ﬁfth iter-
ation. Goodness of ﬁt of the aggregate data models
was assessed using total residual deviance. The total
residual deviance is the mean of the deviance under
the current model minus the deviance for the saturated
model, so that each data point should contribute about
one to the deviance. The effect of the covariates in
the mixed individual patient data and aggregate data
meta-regression was assessed using the deviance infor-
mation criteria.
The aggregate data network meta-analysis was imple-
mented using WinBUGS 1.4.320 and the individual
patient data network meta-analysis was implemented
using OpenBUGS (http://www.openbugs.net/). Code is
available on request.
RESULTS
Study Selection
The literature searches identiﬁed 2,284 citations. Eight
randomized21–28 and two quasi-randomized controlled
trials29,30 satisﬁed the inclusion criteria (participant
numbers ranging from 23 to 207). The authors of seven
of these 10 studies22–26,28,30 provided data from 650
patients for individual patient data meta-analysis. The
process is described in a PRISMA ﬂow diagram (Fig-
ure 1).
Characteristics of Included Studies
Table 1 shows the study characteristics. The studies
were undertaken in Australia,21 France,22,23,25 Ger-
many,26,27,30 Spain,24 Canada,28 and the United States29
and were published between 2000 and 2012. Six
studies21–23,25,29,30 were limited to patients with acute
cardiogenic pulmonary edema and one27 to patients
with exacerbation of chronic obstructive pulmonary dis-
ease. Six studies21–23,25,27,28 evaluated CPAP, and
four24,26,29,30 evaluated BiPAP. One study25 compared
early CPAP to delayed CPAP, while use of in-hospital
NIV in the control arm was allowed in three23,26,28 of
the other studies, prohibited in one,22 and not recorded
in ﬁve.21,24,27,29,30 The results of the individual trials are
presented in Figures 2 and 3 for mortality and intuba-
tion rates, respectively.
Risk of Bias Within Studies
Data Supplements S2 and S3 (available as supporting
information in the online version of this paper) present
the methodologic quality of the included studies. Six
studies22–26,28 achieved positive assessments in at least
six of the nine methodologic quality items. The potential
sources of bias most frequently identiﬁed in studies con-
cerned lack of blinding of outcome assessment and lack
of adequate power to detect differences in the primary
outcome. Two studies29,30 were quasi-randomized stud-
ies: randomization in Weitz et al.30 was based on date
of birth; Craven et al.29 did not provide details on the
method of randomization, although 10 emergency ser-
vice units were divided into ﬁve matched pairs with one
unit from each pair equipped with a BiPAP ventilation
system and one without.
962 Goodacre et al. • PREHOSPITAL NIV META-ANALYSIS
Data Analysis Issues
There were no deaths in the study by Schmidbauer
et al.27 Although the study is included in the analysis for
completeness, the sample data provide no information
about the effect of treatment on mortality. The study-
speciﬁc ORs that are presented in Figures 2 and 3 are
sample estimates and the pooled estimates are from the
random-effects models. There are no feedback loops in
the evidence network so there is not a mixture of direct
and indirect evidence about treatment effects. Conse-
quently, there are no potential inconsistencies in the evi-
dence about treatment effects.
Effects of Interventions
Aggregate Data Network Meta-analysis. Continuous
positive airway pressure is the most effective treatment
on mortality (probability = 0.989), with OR of 0.41 (95%
CrI = 0.20 to 0.77) compared to standard care. There
was considerable uncertainty associated with the effect
of BiPAP relative to standard care (OR = 1.94; 95%
CrI = 0.65 to 6.14). The between-study SD of 0.29 (95%
CrI = 0.02 to 0.85) is indicative of mild heterogeneity
between studies but with considerable uncertainty. Sen-
sitivity analysis excluding two quasi-randomized trials
and one study comparing early prehospital CPAP to late
prehospital CPAP produced similar results, with CPAP
more effective than standard care (OR = 0.45; 95%
CrI = 0.21 to 0.93), while the effect of BiPAP relative to
standard care remained uncertain (OR = 1.95; 95%
CrI = 0.43 to 9.46).
CPAP was estimated to be the most effective treat-
ment on intubation rate (probability = 0.639), with an
OR of 0.32 (95% CrI = 0.17 to 0.62) compared to stan-
dard care. There was uncertainty associated with the
effect of BiPAP relative to standard care (OR = 0.40;
95% CrI = 0.14 to 1.16). The between-study SD of 0.21
(95% CrI = 0.01 to 0.73) is indicative of mild heterogene-
ity between studies but with considerable uncertainty.
Sensitivity analysis excluding one quasi-randomized
trial29 (the other30 did not report intubation rate) and
one study comparing early prehospital CPAP to late
prehospital CPAP25 produced similar results, with CPAP
more effective than standard care (OR = 0.34; 95%
CrI = 0.15 to 0.77), while the effect of BiPAP relative to
standard care remained uncertain (OR = 0.53; 95%
CrI = 0.11 to 2.28).
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abstract 
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(n = 7 studies)
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Figure 1. Study flow chart. IPD = individual patient data; NIV = noninvasive ventilation.
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Mixed Individual Patient Data and Aggregate Data
Network Meta-analysis. Potential treatment effect
modiﬁers were identiﬁed from separate analyses of each
study adjusting treatment effect for age, sex, primary
diagnosis, provider, and various measures of severity of
acute respiratory failure. Age, sex, primary diagnosis,
and respiratory rate were identiﬁed as potential modiﬁ-
ers of the effect of treatment on mortality and sex,
respiratory rate, SpO2, PaO2, and PaCO2 as potential
modiﬁers of the effect of treatment on intubation rate to
be included in the network meta-regression. Data on
prehospital time delay were not well deﬁned or
Figure 2. Comparison of mortality for interventions versus standard care from the primary trials. BiPAP = bilevel inspiratory posi-
tive airway pressure; CPAP = continuous positive airway pressure; CrI = credible interval.
Figure 3. Comparison of intubation for interventions versus standard care from the primary trials. BiPAP = bilevel inspiratory posi-
tive airway pressure; CPAP = continuous positive airway pressure; CrI = credible interval.
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Table 2
Mortality in Prehospital NIV Patients With Acute Respiratory Failure With Continuous Treatment Effect Modifiers:* Posterior Results
for the Odds of Death Relative to Standard Care (Random Effects)
Variable
Potential Treatment Effect Modifier
Age Respiratory Rate
Data source
Individual patient data Ducros,22 Frontin,23 Plaisance,25
Roessler,26 Thompson,28
Mas,24 Weitz30
Ducros,22 Frontin,23 Plaisance,25
Roessler,26 Thompson,27
Mas,24 Weitz30
Aggregate Austin and Wills,21 Craven29 —
Coefficient of treatment effect modifier, OR (95% CrI)
BiPAP 1.04 (0.92-1.18) 0.88 (0.70-1.04)
CPAP 1.02 (0.97-1.08) 0.95 (0.88-1.03)
Treatment effect at the mean value of the treatment effect modifier, OR (95% CrI)
BiPAP 2.44 (0.76-8.71) 2.66 (0.59-15.19)
CPAP 0.40 (0.19-0.77) 0.62 (0.28-1.29)
Between-study SD (95% CrI) 0.31 (0.02-0.87) 0.30 (0.01-0.89)
Deviance information criterion (model with treatment
effect modifier vs. model without treatment effect modifier)
481.80 vs. 470.54 455.99 vs. 451.62
BiPAP = bi-level inspiratory positive airway pressure; CPAP = continuous positive airway pressure; CrI = credible interval;
NIV = noninvasive ventilation.
*Each potential treatment effect modifier was analyzed separately in the model.
Table 3
Mortality in Prehospital NIV Patients With Acute Respiratory Failure With Binary Treatment Effect Modifiers:* Posterior Results for
the Odds of Death Relative to Standard Care (Random Effects)
Variable
Potential Treatment Effect Modifier
Sex ACPO† COPD† Provider
Data source
Individual patient data Ducros,22 Frontin,23
Plaisance,25
Roessler,26
Weitz30
Roessler,26 Mas24 Roessler,26 Thompson,28
Mas24
—
Aggregate Thompson,28
Austin,21
Craven29
Ducros,22 Frontin,23
Plaisance,25
Thompson,28
Austin,21 Craven29
Ducros,22 Frontin,23
Plaisance,25
Austin,21 Craven29
Ducros,22 Frontin,23
Plaisance,25
Roessler,26
Thompson,28
Mas,24 Weitz,30
Austin,21 Craven29
Coefficient of treatment effect modifier, OR (95% CrI)
BiPAP 0.19 (0.01-2.44) 1.45 (0.25-9.44) 0.19 (0.01-1.70) 0.57 (0.06-3.59)
CPAP 0.18 (0.04-0.74) 1.30 (0.25-7.13) 0.27 (0.03-1.92) 1.43 (0.32-6.36)
Treatment effect at the mean value of the treatment effect modifier, OR (95% CrI)
BiPAP Males: 0.55 (0.08-3.40)
Females:
2.92 (0.44-21.82)
Patients with ACPO:
2.07 (0.59-8.11)
Patients without
ACPO: 1.41 (0.28-7.65)
Patients with
COPD: 0.50 (0.04-4.34)
Patients without
COPD: 2.58 (0.82-9.51)
Physicians:
1.29 (0.19-7.45)
Paramedics:
2.31 (0.72-8.83)
CPAP Males: 0.16 (0.05-0.44)
Females:
0.88 (0.34-2.20)
Patients with
ACPO: 0.42 (0.20-0.81)
Patients without
ACPO: 0.32 (0.06-1.60)
Patients with
COPD: 0.12 (0.01-0.83)
Patients without
COPD: 0.45 (0.22-0.87)
Physicians: 0.55
(0.24-1.19)
Paramedics:
0.38 (0.10-1.41)
Between-study SD (95% CrI) 0.32 (0.01-0.89) 0.31 (0.02-0.87) 0.30 (0.01-0.86) 0.25 (0.01-0.80)
Deviance information
criterion (model with
treatment effect modifier
vs. model without treatment
effect modifier)
353.39 vs. 358.43 210.65 vs. 208.36 207.89 vs. 208.46 77.95 vs. 76.32
ACPO = acute cardiopulmonary edema; BiPAP = bi-level inspiratory positive airway pressure; COPD = chronic obstructive pulmo-
nary disease; CPAP = continuous positive airway pressure; CrI = credible interval.
*Each potential treatment effect modifier was analyzed separately in the model.
†Primary diagnosis.
ACADEMIC EMERGENCY MEDICINE • September 2014, Vol. 21, No. 9 • www.aemj.org 967
reported so this was not explored as a potential treat-
ment effect modiﬁer.
Tables 2 and 3 give the results for mortality. The indi-
vidual patient data and aggregate data network meta-
regression suggested that sex was a modiﬁer of the
effect of treatment with CPAP, compared to standard
care on mortality (OR for males relative to females =
0.18; 95% CrI = 0.04 to 0.74). There was insufﬁcient evi-
dence that sex was a modiﬁer of the effect of treatment
with BiPAP compared to standard care on mortality.
Tables 4 and 5 give the results for intubation rate.
The individual patient data and aggregate data network
meta-regression suggested that none of the covariates
were modiﬁers of treatment effect.
Safety and Adverse Events
Safety information was inconsistently recorded and
reported. Three studies25,26,30 reported that no adverse
events were identiﬁed, one study22 reported one case of
vomiting that resolved spontaneously, and one study23
Table 4
Intubation Rates in Prehospital NIV Patients With Acute Respiratory Failure With Continuous Treatment Effect Modifiers:* Posterior
Results for the Odds of Intubation Relative to Standard Care (Random Effects)
Variable
Potential Treatment Effect Modifier
RR SpO2 PaO2 PaCO2
Data source
Individual patient data Ducros,21 Frontin,23
Plaisance,25
Roessler,26 Mas24
Ducros,22 Frontin,23
Plaisance,25
Roessler,26 Mas24
Ducros,22 Frontin,23
Plaisance25
Ducros,22 Frontin,23
Plaisance25
Aggregate Thompson29 Thompson29 — —
Coefficient of treatment effect modifier, OR (95% CrI)
BiPAP 0.94 (0.77-1.12) 1.02 (0.92-1.14) — —
CPAP 0.99 (0.90-1.10) 1.02 (0.95-1.11) 1.0 (0.99-1.02) 1.03 (0.96-1.10)
Treatment effect at the average value of the treatment effect modifier, OR (95% CrI)
BiPAP 0.50 (0.10,2.33) 0.57 (0.08-3.28)
CPAP 0.35 (0.15-0.83) 0.34 (0.15-0.74) 0.38 (0.14-0.97) 0.32 (0.11-0.82)
Between study SD (95% CrI) 0.29 (0.01-0.91) 0.26 (0.01-0.87) 0.24 (0.01-0.81) 0.24 (0.01-0.81)
Deviance information
criterion (model with
treatment effect modifier
vs. model without treatment
effect modifier)
320.76 vs. 318.67 325.83 vs. 318.67 241.17 vs. 234.69 228.30 vs. 234.69
— = analysis not possible; BiPAP = bilevel inspiratory positive airway pressure; CPAP = continuous positive airway pressure;
CrI = credible interval; PaCO2 = arterial carbon dioxide tension; PaO2 = arterial oxygen tension; RR = respiratory rate;
SpO2 = oxygen saturation.
*Each potential treatment effect modifier was analyzed separately in the model.
Table 5
Intubation Rates in Prehospital NIV Patients With Acute Respiratory Failure With Binary Treatment Effect Modifiers:* Posterior
Results for the Odds of Intubation Relative to Standard Care (Standard Oxygen Therapy) (Random Effects)
Variable
Potential Treatment Effect Modifier
Sex Provider
Data source
Individual patient data Ducros,22 Frontin,23 Plaisance,25
Roessler26
—
Aggregate Thompson,28 Craven29 Ducros,22 Frontin,23
Plaisance,25 Roessler,26 Thompson,28
Mas,24 Weitz,30 Austin,21 Craven29
Coefficient of treatment effect modifier, OR (95% CrI)
BiPAP 3.42 (0.26-43.80) 0.46 (0.04-2.81)
CPAP 3.61 (0.78-19.11) 1.12 (0.26-4.59)
Treatment effect at the mean value of the treatment effect modifier, OR (95% CrI)
BiPAP Males: 0.37 (0.06-1.98)
Females: 0.11 (0.02-0.63)
Physicians: 0.23 (0.02-1.21)
Paramedics: 0.51 (0.15-1.70)
CPAP Males: 0.55 (0.21-1.43)
Females: 0.16 (0.04-0.49)
Physicians: 0.33 (0.15-0.70)
Paramedics: 0.30 (0.09-1.00)
Between-study SD (95% CrI) 0.21 (0.01-0.74) 0.23 (0.01-0.80)
Deviance information
criterion (model with treatment effect modifier
vs. model without treatment effect modifier)
298.76 vs. 293.92 80.229 vs. 76.318
BiPAP = bilevel inspiratory positive airway pressure; CPAP = continuous positive airway pressure; CrI = credible interval.
*Each potential treatment effect modifier was analyzed separately in the model.
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reported vomiting as the only adverse event in both
intervention and comparator groups (two of 60 vs. three
of 62, respectively).
Risk of Publication Bias
For completeness and descriptive purposes, funnel plots
were drawn to explore publication bias. There was no
obvious indication of asymmetry, although the number
of studies available was small and less than recom-
mended for statistical hypothesis testing31 (Data Supple-
ment S4, available as supporting information in the
online version of this paper).
DISCUSSION
Prehospital CPAP appears to reduce mortality and intu-
bation rate in acute respiratory failure. The effectiveness
of prehospital BiPAP is uncertain, with estimates of the
effect on mortality and intubation, including the possi-
bility of either worthwhile beneﬁt or potential harm.
The network meta-analysis using a mixture of individual
patient data and aggregate data suggested that male
sex was a signiﬁcant modiﬁer of the effect of treatment
effect on mortality, with CPAP being more effective in
males. It could be postulated that muscle mass allows
CPAP to have an enhanced effect in males, but given
that this was one of a number of associations explored,
it should be interpreted with caution. We found no such
association in the analysis of intubation data.
Two previous meta-analyses of prehospital NIV have
been published.13,14 Williams et al.13 only evaluated pre-
hospital CPAP and included nonrandomized studies.
They reported that CPAP was associated with lower mor-
tality and fewer intubations, with similar ORs to ours.
The inclusion of nonrandomized studies may be inappro-
priate, given their high risk of bias. Our decision to
include quasi-randomized trials could be criticized for
similar reasons, but sensitivity analysis showed similar
results when these were excluded. Mal et al.14 evaluated
prehospital CPAP and BiPAP, but combined results from
studies of these different modalities. They reported that
NIV was associated with a reduction in mortality (relative
risk = 0.58; 95% CI = 0.35 to 0.95) and need for invasive
ventilation (relative risk = 0.37; 95% CI = 0.24 to 0.58).
Our analysis showed that this ﬁnding is conﬁrmed for
prehospital CPAP but not for prehospital BiPAP.
LIMITATIONS
Although our review is the most comprehensive to date,
it is possible that we may have missed studies that were
neither registered nor published, resulting in publica-
tion bias. There were relatively few studies available for
analysis, and the between-study variability was uncer-
tain. The analysis of BiPAP in particular involved fewer
studies and fewer patients (190 vs. 610 receiving CPAP).
Patients eligible for prehospital NIV might be expected
to receive in-hospital NIV if prehospital treatment were
not available, but this was only clearly mandated in one
study. Thus some of the studies may be more appropri-
ately considered as evaluations of NIV per se, rather
than evaluations of prehospital versus in-hospital NIV.
Prehospital NIV was typically delivered by physicians or
paramedics with online physician support in the studies,
so ﬁndings may not be generalizable to prehospital sys-
tems based on paramedics working without physician
support. Safety and adverse events were inconsistently
reported so we are unable to draw reliable conclusions
on these issues. Finally, we did not examine cost-effec-
tiveness, so even if prehospital CPAP is considered
clinically effective, it may not be cost-effective.
CONCLUSIONS
Prehospital continuous positive airway pressure can
reduce mortality and intubation rates for patients with
acute respiratory failure, although the available evidence
may not be generalizable to some prehospital systems. In
particular, existing studies have not all compared prehos-
pital continuous positive airway pressure to in-hospital
noninvasive ventilation and thus may not be generaliz-
able to systems where in-hospital noninvasive ventilation
is standard practice. The substantial cost of implementing
prehospital continuous positive airway pressure means
that evidence of cost-effectiveness is required before
implementation can be recommended. The available evi-
dence does not currently support the use of prehospital
bilevel inspiratory positive airway pressure. Further
research is required in the form of a large pragmatic
study and economic analysis comparing prehospital con-
tinuous positive airway pressure to in-hospital noninva-
sive ventilation for patients with acute respiratory failure.
We thank Gavin Perkins, Matt Ward, and Jerry Penn-Ashman for
providing expert clinical advice and Kathryn MacKellar for clerical
assistance. We thank Rebecca Harvey for creating the forest plots
and funnel plots.
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